Impact of Migraine on Daily Life: Results of the Observational survey of the Epidemiology, Treatment, and Care of Migraine (OVERCOME [Japan]) Study.
Automobile driving
Daily life
Family
Household work
Japan
Leisure activities
Mental health
Migraine disorders
Sleep
Social participation
Journal
Neurology and therapy
ISSN: 2193-8253
Titre abrégé: Neurol Ther
Pays: New Zealand
ID NLM: 101637818
Informations de publication
Date de publication:
04 Jan 2024
04 Jan 2024
Historique:
received:
15
08
2023
accepted:
22
11
2023
medline:
4
1
2024
pubmed:
4
1
2024
entrez:
4
1
2024
Statut:
aheadofprint
Résumé
The impacts of migraine on daily life, including daily activities and fundamental health indicators (sleep and mental health), have not been described in detail for people with migraine in Japan. The cross-sectional ObserVational survey of the Epidemiology, tReatment, and Care Of MigrainE (OVERCOME [Japan]) study was conducted between July and September 2020. Impacts of migraine on housework, family/social/leisure activities, driving, and sleep were assessed using questions from the Migraine Disability Assessment (MIDAS), Migraine-Specific Quality-of-Life Questionnaire, and Impact of Migraine on Partners and Adolescent Children scales and questions developed for OVERCOME (Japan). The Migraine Interictal Burden Scale (MIBS-4) evaluated burden on days without headaches. Depression and anxiety were assessed with the Patient Health Questionnaire (PHQ-8) and Generalized Anxiety Disorder (GAD-7) scales, respectively. Impacts on daily life were also described across MIDAS/MIBS-4 categories. Among 17,071 respondents with migraine, 24.8% required assistance with housework at least sometimes. Migraine interfered with relationships, leisure, and social activities at least sometimes for 31.8%, 41.6%, and 18.0% of respondents, respectively. Between headache days, 26.8% of respondents worried about planning social/leisure activities at least sometimes. Among respondents living with family (N = 13,548), migraine also had impacts on participation in and enjoyment of family activities. Among respondents who drove (N = 10,921), 43.9% reported that symptoms interfered with driving at least sometimes. Migraine interfered with sleep and mood at least sometimes for 52.7% and 70.7% of respondents, respectively. PHQ-8 and GAD-7 thresholds for clinical depression and anxiety were met by 28.6% and 22.0% of respondents, respectively. Impact of migraine on daily life increased with increasing severity of MIDAS/MIBS-4 categories. The burden of migraine on daily activities, sleep, and mental health is substantial for people with migraine in Japan. In clinical practice, it is important to evaluate the impact of migraine on daily life in addition to migraine symptoms.
Identifiants
pubmed: 38175489
doi: 10.1007/s40120-023-00569-3
pii: 10.1007/s40120-023-00569-3
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Eli Lilly and Company
ID : Study funding
Organisme : Eli Lilly Japan
ID : Funding for analysis
Organisme : Eli Lilly Japan
ID : medical writing
Organisme : Eli Lilly Japan
ID : publication fees
Organisme : Daiichi-Sankyo
ID : Funding for medical writing
Informations de copyright
© 2024. The Author(s).
Références
Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38(1):1–211.
doi: 10.1177/0333102417738202
Steiner TJ, Stovner LJ, Jensen R, Uluduz D, Katsarava Z, on behalf of Lifting The Burden: the Global Campaign against Headache. Migraine remains second among the world’s causes of disability, and first among young women: findings from GBD2019. J Headache Pain. 2020;21(1):137.
doi: 10.1186/s10194-020-01208-0
pubmed: 33267788
pmcid: 7708887
Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache. 2001;41(7):646–57.
doi: 10.1046/j.1526-4610.2001.041007646.x
pubmed: 11554952
Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007;68(5):343–9.
doi: 10.1212/01.wnl.0000252808.97649.21
pubmed: 17261680
Matsumori Y, Ueda K, Komori M, et al. Burden of migraine in Japan: results of the ObserVational survey of the Epidemiology, tReatment, and Care Of MigrainE (OVERCOME [Japan]) study. Neurol Ther. 2022;11(1):205–22.
doi: 10.1007/s40120-021-00305-9
pubmed: 34862581
Kikui S, Chen Y, Todaka H, Asao K, Adachi K, Takeshima T. Burden of migraine among Japanese patients: a cross-sectional National Health and Wellness Survey. J Headache Pain. 2020;21(1):110.
doi: 10.1186/s10194-020-01180-9
pubmed: 32912187
pmcid: 7488335
Igarashi H, Ueda K, Jung S, Cai Z, Chen Y, Nakamura T. Social burden of people with the migraine diagnosis in Japan: evidence from a population-based cross-sectional survey. BMJ Open. 2020;10(11): e038987.
doi: 10.1136/bmjopen-2020-038987
pubmed: 33168555
pmcid: 7654137
Ueda K, Ye W, Lombard L, et al. Real-world treatment patterns and patient-reported outcomes in episodic and chronic migraine in Japan: analysis of data from the Adelphi migraine disease specific programme. J Headache Pain. 2019;20(1):68.
doi: 10.1186/s10194-019-1012-1
pubmed: 31174464
pmcid: 6734304
Buse DC, Bigal MB, Rupnow M, Reed ML, Serrano D, Lipton R. Development and validation of the Migraine Interictal Burden Scale (MIBS): a self-administered instrument for measuring the burden of migraine between attacks [abstract S05.003]. Neurology. 2007;68:A89.
Buse DC, Rupnow MFT, Lipton RB. Assessing and managing all aspects of migraine: migraine attacks, migraine-related functional impairment, common comorbidities, and quality of life. Mayo Clin Proc. 2009;84(5):422–35.
doi: 10.1016/S0025-6196(11)60561-2
pubmed: 19411439
pmcid: 2676125
Burch RC, Buse DC, Lipton RB. Migraine: epidemiology, burden, and comorbidity. Neurol Clin. 2019;37(4):631–49.
doi: 10.1016/j.ncl.2019.06.001
pubmed: 31563224
Hirata K, Ueda K, Komori M, et al. Comprehensive population-based survey of migraine in Japan: results of the ObserVational survey of the Epidemiology, tReatment, and Care Of MigrainE (OVERCOME [Japan]) study. Curr Med Res Opin. 2021;37(11):1945–55.
doi: 10.1080/03007995.2021.1971179
pubmed: 34429000
Takeshima T, Ueda K, Komori M, et al. Potential unmet needs in acute treatment of migraine in Japan: results of the OVERCOME (Japan) study. Adv Ther. 2022;39(11):5176–90.
doi: 10.1007/s12325-022-02289-w
pubmed: 36089637
pmcid: 9525323
Hirata K, Komori M, Ueda K, et al. Outcomes and factors associated with insufficient effectiveness of acute treatments of migraine in Japan: results of the ObserVational survey of the Epidemiology, tReatment, and Care Of MigrainE (OVERCOME [Japan]) study. Drugs Real World Outcomes. 2023;10:415–28.
doi: 10.1007/s40801-023-00368-0
pubmed: 37278957
pmcid: 10491570
Silberstein S, Loder E, Diamond S, Reed ML, Bigal ME, Lipton RB. Probable migraine in the United States: results of the American Migraine Prevalence and Prevention (AMPP) study. Cephalalgia. 2007;27(3):220–9.
doi: 10.1111/j.1468-2982.2006.01275.x
pubmed: 17263769
Stewart WF, Lipton RB, Dowson AJ, Sawyer J. Development and testing of the Migraine Disability Assessment (MIDAS) Questionnaire to assess headache-related disability. Neurology. 2001;56(6 Suppl 1):S20–8.
pubmed: 11294956
Iigaya M, Sakai F, Kolodner KB, Lipton RB, Stewart WF. Reliability and validity of the Japanese Migraine Disability Assessment (MIDAS) Questionnaire. Headache. 2003;43(4):343–52.
doi: 10.1046/j.1526-4610.2003.03069.x
pubmed: 12656705
Martin BC, Pathak DS, Sharfman MI, et al. Validity and reliability of the migraine-specific quality of life questionnaire (MSQ Version 2.1). Headache. 2000;40(3):204–15.
doi: 10.1046/j.1526-4610.2000.00030.x
pubmed: 10759923
Ohbu S, Igarashi H, Okayasu H, et al. Development and testing of the Japanese version of the migraine-specific quality of life instrument. Qual Life Res. 2004;13(8):1489–93.
doi: 10.1023/B:QURE.0000040787.20364.89
pubmed: 15503844
Lipton RB, Buse DC, Adams AM, Varon SF, Fanning KM, Reed ML. Family impact of migraine: development of the Impact of Migraine on Partners and Adolescent Children (IMPAC) scale. Headache. 2017;57(4):570–85.
doi: 10.1111/head.13028
pubmed: 28185239
pmcid: 5396278
Takeshima T, Ooba S, Hanaoka Y, et al. Impact of migraine on family members: an investigation by Impact of Migraine on Partners and Adolescent Children (IMPAC) scale. Rinsho Shinkeigaku. 2023;63(12):813–23. (in Japanese)
doi: 10.5692/clinicalneurol.cn-001903
pubmed: 37989287
Kroenke K, Strine TW, Spitzer RL, Williams JB, Berry JT, Mokdad AH. The PHQ-8 as a measure of current depression in the general population. J Affect Disord. 2009;114(1–3):163–73.
doi: 10.1016/j.jad.2008.06.026
pubmed: 18752852
Muramatsu K, Miyaoka H, Kamijima K, et al. The patient health questionnaire, Japanese version: validity according to the mini-international neuropsychiatric interview-plus. Psychol Rep. 2007;101(3 Pt 1):952–60.
pubmed: 18232454
Spitzer RL, Kroenke K, Williams JB, Löwe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006;166(10):1092–7.
doi: 10.1001/archinte.166.10.1092
pubmed: 16717171
Muramatsu K, Muramatsu Y, Miyaoka H, et al. Validation and utility of a Japanese version of the GAD-7. Panminerva Medica 20th World Congress on Psychosomatic Medicine. Abstract book. 2009;51(3 Suppl 1):79.
Takeshima T, Ishizaki K, Fukuhara Y, et al. Population-based door-to-door survey of migraine in Japan: the Daisen study. Headache. 2004;44(1):8–19.
doi: 10.1111/j.1526-4610.2004.04004.x
pubmed: 14979878
Sakai F, Hirata K, Igarashi H, et al. A study to investigate the prevalence of headache disorders and migraine among people registered in a health insurance association in Japan. J Headache Pain. 2022;23(1):70.
doi: 10.1186/s10194-022-01439-3
pubmed: 35733104
pmcid: 9219245
Buse DC, Scher AI, Dodick DW, et al. Impact of migraine on the family: perspectives of people with migraine and their spouse/domestic partner in the CaMEO study. Mayo Clin Proc. 2016;S0025–6196(16):00126–9.
Tepper SJ, Silberstein SD, Rosen NL, et al. The influence of migraine on driving: current understanding, future directions, and potential implications of findings. Headache. 2020;60(1):178–89.
doi: 10.1111/head.13716
pubmed: 31792964
Duan S, Ren Z, Xia H, Wang Z, Zheng T, Liu Z. Association between sleep quality, migraine and migraine burden. Front Neurol. 2022;13:955298.
doi: 10.3389/fneur.2022.955298
pubmed: 36090858
pmcid: 9459411
Lipton RB, Hamelsky SW, Kolodner KB, Steiner TJ, Stewart WF. Migraine, quality of life, and depression: a population-based case-control study. Neurology. 2000;55(5):629–35.
doi: 10.1212/WNL.55.5.629
pubmed: 10980724
Song TJ, Cho SJ, Kim WJ, Yang KI, Yun CH, Chu MK. Anxiety and depression in probable migraine: a population-based study. Cephalalgia. 2017;37(9):845–54.
doi: 10.1177/0333102416653235
pubmed: 27250234
Ueda M, Stickley A, Sueki H, Matsubayashi T. Mental health status of the general population in Japan during the COVID-19 pandemic. Psychiatry Clin Neurosci. 2020;74(9):505–6.
doi: 10.1111/pcn.13105
pubmed: 32609413
pmcid: 7361838
Shimizu T, Sakai F, Miyake H, et al. Disability, quality of life, productivity impairment and employer costs of migraine in the workplace. J Headache Pain. 2021;22(1):29.
doi: 10.1186/s10194-021-01243-5
pubmed: 33882816
pmcid: 8061063
Wolf J, Danno D, Takeshima T, Vancleef LM, Yoshikawa H, Gaul C. The relation between emotion regulation and migraine: a cross-cultural study on the moderating effect of culture. Cephalalgia. 2020;40(4):384–92.
doi: 10.1177/0333102419885394
pubmed: 31690115
Cerner Enviza. Stigma (ELICIT mini series—Issue 1). Cerner Corporation; 2022.
Awaki E. Migraine treatment that takes gender differences into account. Jpn J Headache. 2023;50(1):135–9 (in Japanese).